U.S. markets close in 5 hours 47 minutes

iBio, Inc. (IBIO)

NYSE American - Nasdaq Real Time Price. Currency in USD
1.1986-0.0514 (-4.11%)
As of 10:07AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close1.2500
Bid1.1900 x 4000
Ask1.2500 x 1100
Day's Range1.1815 - 1.2201
52 Week Range1.0200 - 52.0000
Avg. Volume154,073
Market Cap4.176M
Beta (5Y Monthly)-3.80
PE Ratio (TTM)N/A
EPS (TTM)-15.3700
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for IBIO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • iBio, Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is a diversified healthcare company that develops, manufactures and markets products in two business segments: Innovative Medicine (formerly Pharmaceuticals) and MedTech.
    Fair Value
    Economic Moat
    last monthArgus Research
View more
  • GlobeNewswire

    iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

    – Deal includes $1 million upfront and potential future milestone payments – – iBio’s proprietary therapeutic pipeline will now be comprised entirely of promising immuno-oncology candidates – BRYAN, Texas and SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announces today that it has entered into an asset purchase agreement (“Agreement”) with Otsuka Pharmaceutical Co., Ltd. (“Otsuka”), p

  • GlobeNewswire

    iBio Announces Participation in 23rd Annual PepTalk Conference

    - VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning -BRYAN, Texas and SAN DIEGO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that Matthew P. Greving Ph.D., its Vice President and Head of Platform Technologies and Machine Learning, will give a podium presentation titled "En

  • GlobeNewswire

    iBio Amends and Extends Maturity of Credit Agreement

    – Extends maturity date to March 29, 2024 – – Allows for more time to complete planned divestiture of legacy CDMO business - BRYAN, Texas and SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced its wholly owned subsidiary, iBio CDMO LLC, and its lender, Woodforest National Bank (“Woodforest”), have entered into an amendment (the “Amendment”) to the Credit Agreement dated Nove